Cellebrite shares plunge 31% after missing revenue, cutting FY26 guidance
Cellebrite DI shares fell sharply after missing Q2 revenue targets and cutting FY26 guidance. CEO Shiv Ramji cited government procurement delays as the cause. The stock hit a 52-week low of $10.46.
*this image is generated using AI for illustrative purposes only.
Cellebrite DI Ltd (NASDAQ: CLBT) shares plummeted 31.41% to $10.46 on Thursday, hitting a new 52-week low after the cybersecurity firm reported second-quarter results that missed top-line expectations and downgraded its full-year 2026 revenue guidance.
The company posted adjusted earnings per share of $0.11, aligning with analyst consensus but representing an 8.33% decline from the $0.12 per share reported in the same period last year. However, quarterly revenue reached $131.14 million, falling short of the consensus estimate of $131.87 million despite a 15.8% year-over-year increase from $113.28 million.
Guidance Cut Amid Execution Challenges
Looking ahead, Cellebrite lowered its outlook for the remainder of the fiscal year. The company expects third-quarter sales between $145 million and $148 million, below market consensus of $150.3 million. Additionally, full-year 2026 sales guidance was reduced to a range of $555 million to $561 million, down from the previous forecast of $565 million to $571 million and under Wall Street’s projection of $568.05 million.
Newly appointed CEO Shiv Ramji addressed the performance during the earnings call, taking direct responsibility for the missed targets. Ramji stated that the shortfall stemmed from timing delays on large transactions with U.S. federal and European government customers who are encountering new procurement requirements.
"We did not deliver the ARR and revenue performance we expected in the second quarter," Ramji said. He emphasized that leadership is implementing greater rigor around sales execution and tightening forecasting discipline moving forward.
What the Numbers Show
The divergence between strong year-over-year revenue growth of nearly 16% and a contraction in net profitability highlights significant margin pressure. While the company expanded its top line, it failed to meet even modest analyst expectations for both current quarter revenue and future guidance. The sharp decline in share price reflects investor concern over the execution risks associated with large government contracts and the potential for further procurement-related delays in upcoming quarters.
How will the new procurement requirements from U.S. federal and European governments impact Cellebrite's sales cycle length and deal closure rates in Q3 2026?
What specific operational changes is CEO Shiv Ramji implementing to improve forecasting discipline and mitigate execution risks in large government contracts?
Will the margin pressure highlighted by the divergence between revenue growth and net profitability persist as the company scales its operations under the new leadership?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
